Skip to main content

Osang Healthcare, Nexus Dx Ink Manufacturing, Supply Agreement for SARS-CoV-2 RT-PCR Kit

NEW YORK ─ Osang Healthcare and Nexus Dx on Monday announced a manufacturing and supply agreement for Osang's GeneFinder COVID-19 Plus RealAmp Kit, which detects SARS-CoV-2 through RT-PCR and provides 96 test results in just over two hours at the point of care.

Under the agreement, Nexus Dx will manufacture the kit at its facility in San Diego.

Financial and other terms of the agreement were not disclosed.

South Korea-based Osang is seeking US Food and Drug Administration Emergency Use Authorization for its PCR-based rapid diagnostic kit and plans to distribute it to US airports for immigration-quarantine purposes.

The company views its partnership with Nexus Dx, part of Hennigsdorf, Germany-based Sphingotec, "as a prelude to yet closer collaboration as we explore the expansion of operations and localized manufacturing in the USA," Dong-Hyun Lee, Osang's chairman and CEO, said in a statement.

The collaboration "should greatly improve the speed and efficiency" by which Osang rolls out new products, including a combination COVID-19/Influenza A&B test in the short term, he added.

In May, New York City-based SG Blocks, which designs and builds structures using maritime-grade shipping containers, acquired nonexclusive US distribution rights to the GeneFinder COVID-19 Plus RealAmp Kit.